| RS2526118615 |
LAMC2
|
Health Risk |
Likely pathogenic |
Junctional epidermolysis bullosa gravis of Herlitz, Junctional epidermolysis bullosa gravis of Herlitz |
| RS2526121770 |
LAMC2
|
Health Risk |
Likely pathogenic |
Junctional epidermolysis bullosa gravis of Herlitz, Junctional epidermolysis bullosa gravis of Herlitz |
| RS2526122417 |
LAMC2
|
Health Risk |
Pathogenic |
— |
| RS2526127239 |
LAMC2
|
Health Risk |
Likely pathogenic |
Junctional epidermolysis bullosa gravis of Herlitz, Junctional epidermolysis bullosa gravis of Herlitz |
| RS2526127586 |
LAMC2
|
Health Risk |
Likely pathogenic |
Junctional epidermolysis bullosa gravis of Herlitz, Junctional epidermolysis bullosa gravis of Herlitz |
| RS2526127700 |
LAMC2
|
Health Risk |
Likely pathogenic |
Junctional epidermolysis bullosa gravis of Herlitz, Junctional epidermolysis bullosa gravis of Herlitz |
| RS2526133602 |
LAMC2
|
Health Risk |
Pathogenic |
— |
| RS2526134840 |
LAMC2
|
Health Risk |
Likely pathogenic |
— |
| RS2526140861 |
NOTCH2
|
Health Risk |
Pathogenic |
Hajdu-Cheney syndrome, Hajdu-Cheney syndrome |
| RS2526141876 |
NOTCH2
|
Health Risk |
Pathogenic |
Alagille syndrome due to a NOTCH2 point mutation, Alagille syndrome due to a NOTCH2 point mutation |
| RS2526147354 |
LAMC2
|
Health Risk |
Pathogenic |
Epidermolysis bullosa, junctional 3A |
| RS2526147658 |
LAMC2
|
Health Risk |
Likely pathogenic |
Epidermolysis bullosa, junctional 3B |
| RS2526149314 |
NOTCH2
|
Health Risk |
Pathogenic |
Hajdu-Cheney syndrome, Hajdu-Cheney syndrome |
| RS2526152738 |
NPHS2
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, type 2 |
| RS2526152872 |
SPTA1
|
Health Risk |
Likely pathogenic |
— |
| RS2526152917 |
SPTA1
|
Health Risk |
Likely pathogenic |
— |
| RS2526183021 |
SPTA1
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2526183559 |
SPTA1
|
Health Risk |
Likely pathogenic |
— |
| RS2526190236 |
COL11A1
|
Health Risk |
Likely pathogenic |
Marshall syndrome, Marshall syndrome |
| RS2526191812 |
NPHS2
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, type 2 |
| RS2526206561 |
NOTCH2
|
Health Risk |
Likely pathogenic |
Hajdu-Cheney syndrome, Hajdu-Cheney syndrome |
| RS2526214510 |
TSHB
|
Health Risk |
Pathogenic |
— |
| RS2526216886 |
TSHB
|
Health Risk |
Pathogenic |
— |
| RS2526221510 |
SPTA1
|
Health Risk |
Likely pathogenic |
Pyropoikilocytosis, hereditary |
| RS2526224355 |
ASH1L
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal dominant 52 |
| RS2526234131 |
SLC19A2
|
Health Risk |
Pathogenic |
— |
| RS2526234318 |
MPZ
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease, type I |
| RS2526235696 |
MPZ
|
Health Risk |
Likely pathogenic |
Dejerine-Sottas disease, Dejerine-Sottas disease |
| RS2526235908 |
MPZ
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease, type I |
| RS2526236007 |
COL11A1
|
Health Risk |
Pathogenic |
— |
| RS2526236083 |
MPZ
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease, type I |
| RS2526236106 |
SLC19A2
|
Health Risk |
Pathogenic |
— |
| RS2526236168 |
MPZ
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease, type I |
| RS2526237995 |
MPZ
|
Health Risk |
Likely pathogenic |
Roussy-Lévy syndrome, Roussy-Lévy syndrome |
| RS2526238022 |
MPZ
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2526238512 |
LMX1A
|
Health Risk |
Pathogenic |
Autosomal dominant nonsyndromic hearing loss 7, Autosomal dominant nonsyndromic hearing loss 7 |
| RS2526238682 |
MPZ
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease, type I |
| RS2526238696 |
MPZ
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2J, Charcot-Marie-Tooth disease type 2J |
| RS2526238723 |
MPZ
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Charcot-Marie-Tooth disease |
| RS2526239029 |
MPZ
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease, type I |
| RS2526239717 |
SLC19A2
|
Health Risk |
Pathogenic |
— |
| RS2526240098 |
SLC19A2
|
Health Risk |
Pathogenic |
— |
| RS2526240104 |
SLC19A2
|
Health Risk |
Pathogenic |
— |
| RS2526240389 |
SLC19A2
|
Health Risk |
Likely pathogenic |
— |
| RS2526243073 |
MPZ
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 1B, Charcot-Marie-Tooth disease type 1B |
| RS2526243453 |
MPZ
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2526244215 |
MPZ
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease dominant intermediate D, Charcot-Marie-Tooth disease dominant intermediate D |
| RS2526247353 |
NPHS2
|
Health Risk |
Likely pathogenic |
— |
| RS2526256135 |
SLC19A2
|
Health Risk |
Pathogenic |
— |
| RS2526256716 |
FMO3
|
Health Risk |
Pathogenic |
— |
| RS2526256741 |
SLC19A2
|
Health Risk |
Pathogenic |
— |
| RS2526256749 |
FMO3
|
Health Risk |
Pathogenic |
— |
| RS2526256800 |
FMO3
|
Health Risk |
Pathogenic |
— |
| RS2526256922 |
SLC19A2
|
Health Risk |
Pathogenic |
— |
| RS2526257147 |
SLC19A2
|
Health Risk |
Likely pathogenic |
— |
| RS2526257236 |
FMO3
|
Health Risk |
Pathogenic |
— |
| RS2526257326 |
SLC19A2
|
Health Risk |
Pathogenic/Likely pathogenic |
Megaloblastic anemia, thiamine-responsive |
| RS2526263331 |
TARS2
|
Health Risk |
Likely pathogenic |
Combined oxidative phosphorylation defect type 21, Combined oxidative phosphorylation defect type 21 |
| RS2526272114 |
NPHS2
|
Health Risk |
Pathogenic |
— |
| RS2526272763 |
NPHS2
|
Health Risk |
Pathogenic |
— |
| RS2526273002 |
NPHS2
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, type 2 |
| RS2526273309 |
NPHS2
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, type 2 |
| RS2526273372 |
NPHS2
|
Health Risk |
Pathogenic |
— |
| RS2526273422 |
NPHS2
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, type 2 |
| RS2526273640 |
NPHS2
|
Health Risk |
Pathogenic |
— |
| RS2526274169 |
SLC19A2
|
Health Risk |
Pathogenic |
— |
| RS2526281838 |
SETSIP
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 58 |
| RS2526286396 |
CCDC39
|
Health Risk |
Pathogenic |
Primary ciliary dyskinesia, Primary ciliary dyskinesia |
| RS2526288126 |
NPHS2
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, type 2 |
| RS2526288141 |
NPHS2
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, type 2 |
| RS2526288643 |
NPHS2
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, type 2 |
| RS2526288830 |
NPHS2
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, type 2 |
| RS2526289187 |
SPTA1
|
Health Risk |
Likely pathogenic |
Pyropoikilocytosis, hereditary |
| RS2526289582 |
SPTA1
|
Health Risk |
Likely pathogenic |
— |
| RS2526289681 |
CTRC
|
Health Risk |
Likely pathogenic |
Hereditary pancreatitis, Hereditary pancreatitis |
| RS2526290117 |
CTRC
|
Health Risk |
Pathogenic |
Hereditary pancreatitis, Hereditary pancreatitis |
| RS2526297384 |
CTRC
|
Health Risk |
Likely pathogenic |
Hereditary pancreatitis, Hereditary pancreatitis |
| RS2526297442 |
CTRC
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary pancreatitis, Hereditary pancreatitis |
| RS2526297492 |
NPHS2
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, type 2 |
| RS2526297786 |
NPHS2
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, type 2 |
| RS2526300115 |
NOTCH2
|
Health Risk |
Conflicting classifications of pathogenicity |
Hajdu-Cheney syndrome, NOTCH2-related disorder |
| RS2526300230 |
NOTCH2
|
Health Risk |
Likely pathogenic |
Alagille syndrome due to a NOTCH2 point mutation, Alagille syndrome due to a NOTCH2 point mutation |
| RS2526310648 |
COL6A1
|
Health Risk |
Pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2526312925 |
FMO3
|
Health Risk |
Pathogenic |
— |
| RS2526313561 |
NPHS2
|
Health Risk |
Pathogenic/Likely pathogenic |
Nephrotic syndrome, type 2 |
| RS2526313922 |
NOTCH2
|
Health Risk |
Pathogenic |
Hajdu-Cheney syndrome, Hajdu-Cheney syndrome |
| RS2526314427 |
NPHS2
|
Health Risk |
Pathogenic |
Nephrotic syndrome, type 2 |
| RS2526317363 |
COL6A1
|
Health Risk |
Likely pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2526321732 |
COL6A1
|
Health Risk |
Pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2526321787 |
COL6A1
|
Health Risk |
Pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2526321843 |
COL6A1
|
Health Risk |
Pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2526322096 |
COL6A1
|
Health Risk |
Likely pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2526323385 |
COL6A1
|
Health Risk |
Likely pathogenic |
— |
| RS2526323439 |
COL6A1
|
Health Risk |
Likely pathogenic |
Proximal muscle weakness, Proximal muscle weakness |
| RS2526325667 |
COL6A1
|
Health Risk |
Pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2526326141 |
COL6A1
|
Health Risk |
Likely pathogenic |
Bethlem myopathy 1A, Bethlem myopathy 1A |
| RS2526327036 |
PRG4
|
Health Risk |
Likely pathogenic |
Camptodactyly-arthropathy-coxa vara-pericarditis syndrome, Camptodactyly-arthropathy-coxa vara-pericarditis syndrome |
| RS2526327208 |
FMO3
|
Health Risk |
Pathogenic |
— |
| RS2526328903 |
COL6A1
|
Health Risk |
Likely pathogenic |
COL6A1-related disorder, COL6A1-related disorder |
| RS2526329601 |
FMO3
|
Health Risk |
Pathogenic |
— |